Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials

Arnaud Bayle, Laila Belcaid, Sophie Cousin, Kilian Trin, Melissa Alame, Etienne Rouleau, Isabelle Soubeyran, Ludovic Lacroix, Laura Blouin, Damien Vasseur, Amandine Crombe, Simone Mathoulin-Pelissier, Jean Charles Soria, Carine Bellera, Antoine Italiano

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    Résumé

    Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.

    langue originaleAnglais
    Numéro d'article227
    journalnpj Precision Oncology
    Volume8
    Numéro de publication1
    Les DOIs
    étatPublié - 1 déc. 2024

    Contient cette citation